Table 5 Summary of treatment trials in... | American Society of Hematology

Table 5

Summary of treatment trials in T-PLL

Study	Regimen	No.	CR, %	ORR, %	Medial PFS, mo	Median OS, mo
Mercieca²⁵	Pentostatin*	55 pretreated	9	45	6	9
Dearden²¹	Alemtuzumab (IV)	39 pretreated	60	76	7	10
Keating³⁵	Alemtuzumab (IV)*†	76 pretreated	38	50	4.5	7.5
Dearden²²	Alemtuzumab (IV)	32 previously untreated	81	91	67% at 1 y	37% at 4 y
Hopfinger³³	FMC, then	9 pretreated	24 (FMC)	Total 92	11.5	17.1
	Alemtuzumab (IV)	16 previously untreated	48 (alemtuzumab)	17/25 = 68% after FMC
				20/21 = 95% after alemtuzumab
Ravandi³⁴	Pentostatin + alemtuzumab (IV)	13 (treated + untreated)	62	69	7.8	10.2

Study	Regimen	No.	CR, %	ORR, %	Medial PFS, mo	Median OS, mo
Mercieca²⁵	Pentostatin*	55 pretreated	9	45	6	9
Dearden²¹	Alemtuzumab (IV)	39 pretreated	60	76	7	10
Keating³⁵	Alemtuzumab (IV)*†	76 pretreated	38	50	4.5	7.5
Dearden²²	Alemtuzumab (IV)	32 previously untreated	81	91	67% at 1 y	37% at 4 y
Hopfinger³³	FMC, then	9 pretreated	24 (FMC)	Total 92	11.5	17.1
	Alemtuzumab (IV)	16 previously untreated	48 (alemtuzumab)	17/25 = 68% after FMC
				20/21 = 95% after alemtuzumab
Ravandi³⁴	Pentostatin + alemtuzumab (IV)	13 (treated + untreated)	62	69	7.8	10.2

CR indicates complete remission; ORR, overall response rate; MPFS, median progression-free survival; and MS, median overall survival.

Retrospective analysis.

Compassionate-use trial.